Prasugrel

Another view on prasugrel.

Thromb Haemost 2009; 101: 12–13 The combination of aspirin with clopidogrel is currently the mainstay of antiplatelet therapy for patients with acute coronary syndromes (ACS) (1). While aspirin inhibits platelet thromboxane A2 production and platelet activation, clopidogrel inhibits adenosine diphosphate (ADP)-induced platelet activation by blocking the P2Y12 platelet receptor. When added to as...

Efient, INN-prasugrel

Prasugrel metabolites inhibit neutrophil functions.

Clopidogrel and prasugrel belong to a thienopyridine class of oral antiplatelet drugs that, after having been metabolized in the liver, can inhibit platelet function by irreversibly antagonizing the P2Y(12) receptor. Furthermore, thienopyridines influence numerous inflammatory conditions, but their effects on neutrophils have not been evaluated, despite the important role of these cells in infl...

[On the metabolism of prasugrel].

We read with interest the editorial by Drs. Freedman and Iafrati recently published in Revista Española de Cardiologı́a. The editorial mentions that prasugrel is an inhibitor of the P2Y12 receptor, that it is not metabolized in the liver, and that it does not appear to be affected by the variability of isozyme P450. We believe that it might be a good idea here to indicate the pharmacokinetic cha...

Prasugrel-Induced Hypersensitivity Skin Reaction

We report a case of hypersensitivity skin reaction to prasugrel. The patient exhibited a generalized skin rash after treatment with prasugrel, which was resolved after discontinuation of prasugrel and substitution to clopidogrel. Clopidogrel was successfully administered as an alternative to prasugrel without any signs of further hypersensitivity.